This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George Rice, MD, FRCPC
From the Multiple Sclerosis Clinic, University of Western Ontario, London.

Arch Neurol. 2001;58:1297-1298.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE DEVELOPMENT of neutralizing antibodies (NABs) against interferons is well described in patients with viral hepatitis and with some cancers that are treated with interferon.¹ In patients with hepatitis or cancer, the development of NABs has been associated with reduction of interferon-related adverse effects (eg, fever, chills, and myalgia) and with the recurrence of disease activity. Treatment failure due to NABs in such patients has been much easier to identify, by measuring the more sensitive disease activity markers (eg, transaminase levels in patients with hepatitis or tumor or tumor markers in patients with cancer).

The development of NABs in patients with multiple sclerosis (MS) treated with interferons is a more recent observation, which has generated substantial controversy.² Approximately one third of patients treated with interferon beta-1b developed NABs in the pivotal trial of that agent.³ The NABs were identified by neutralization of a standard dose of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
Farrell et al.
Mult Scler 2008;14:212-218.
ABSTRACT  

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
Sominanda et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:57-62.
ABSTRACT | FULL TEXT  

Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis
Farrell and Giovannoni
Mult Scler 2007;13:567-577.
ABSTRACT  

Not every patient with multiple sclerosis should be treated at time of diagnosis.
Pittock et al.
Arch Neurol 2006;63:611-614.
FULL TEXT  

An improved ELISA for screening for neutralizing anti-IFN-{beta} antibodies in MS patients
Pachner
Neurology 2003;61:1444-1446.
ABSTRACT | FULL TEXT  

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
Giovannoni et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:465-469.
FULL TEXT